# The Synergism Or Long Duration (SOLD) Study

> **NCT00593697** · PHASE3 · COMPLETED · sponsor: **Finnish Breast Cancer Group** · enrollment: 2168 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** trastuzumab (9 weeks) + docetaxel
- **DRUG:** trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)

## Key facts

- **NCT ID:** NCT00593697
- **Lead sponsor:** Finnish Breast Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 2168 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00593697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00593697, "The Synergism Or Long Duration (SOLD) Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00593697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*